NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
SMS Pharma Q2 FY27 Call: Revenue Rises 30% to ₹316 Cr, Capex of ₹280 Cr on Track
SMS Pharmaceuticals hosted its Q2 and H1 FY27 earnings call detailing strong operational momentum. Q2 FY27 revenue grew 30% YoY to ₹316 crore, driven by 47% growth in ARVs (₹150 crore in H1) and 25% growth in anti-inflammatory APIs. EBITDA stood at ₹68 crore with margins expanding 145 bps YoY to 21%, while PAT jumped 57% YoY to ₹39.6 crore. Management raised FY27 guidance, expecting to exceed 15% revenue growth and 20% EBITDA margin, supported by an ongoing ₹280 crore capex (₹160 crore already deployed).
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the formal transcript for the Q2 & H1 FY27 analyst call containing operational metrics, peptide strategy, and raised FY27 outlook.
ஏன் இது முக்கியம்Demonstrates structural margin gains from backward integration (EBITDA margin at 21%) and diversification into higher-margin peptides and CDMO platforms.
Q2 FY27 Revenue: ₹316 கோடிQ2 FY27 PAT: ₹39.6 கோடிTotal capex program: ₹280 கோடிCapex deployed to date: ₹160 கோடிCapex vs TTM revenue: ~31.2%Target Ibuprofen capacity: 9,600 tons a year
📅 குறுகிய காலம்Positive sentiment backed by upward revision of guidance and strong quarterly operating performance.
📈 நீண்ட காலம்Completion of the ₹280 crore capex, launch of 6-8 new molecules in FY28, and scale-up of SMS Peptides could structurally broaden product mix and lift asset turnover.
⚠ அபாய எச்சரிக்கைகள்
High working capital cycle of 120-150 days
Client concentration risk (top 5 customers historically formed 56% of revenue)
Execution risk on commercialization and client acquisition for the new peptide CDMO platform
👀 கவனிக்க வேண்டியவை
Track the commissioning of the remaining ₹120 crore capex by end-FY27 and commercialization of pilot peptide capacity in Q4 FY27.
Q2FY27 PAT up 57% YoY to ₹39.85 Cr; Revenue grows 30% to ₹316.08 Cr
SMS Pharmaceuticals reported strong Q2FY27 results with revenue from operations rising 30% YoY and 53% QoQ to ₹316.08 crore, driven by anti-inflammatory and ARV APIs. EBITDA rose 40% YoY to ₹67.65 crore with margins expanding 145 bps to 21%. Consolidated PAT grew 57% YoY to ₹39.85 crore, while H1FY27 PAT reached ₹60.75 crore (up 33% YoY). Management confirmed that its ₹280 crore capex program is on track (₹160 crore deployed so far) and raised its full-year guidance outlook.
உச்சம் நம்பிக்கை
என்ன மாறியதுSMS Pharma announced its Q2 & H1 FY27 financial results and stated that full-year FY27 growth and EBITDA margins are now expected to surpass earlier guidance.
ஏன் இது முக்கியம்Demonstrates operating leverage and margin expansion from backward integration; ongoing ₹280 crore capex (31% of TTM revenue) provides structural capacity for 6-8 new molecules.
Q2FY27 Revenue: ₹316.08 கோடிQ2FY27 PAT: ₹39.85 கோடிQ2FY27 EBITDA Margin: 21%Total Planned Capex: ₹280 கோடிCapex vs TTM Revenue: ~31.2%Capex Deployed to Date: ₹160 கோடி
📅 குறுகிய காலம்Positive sentiment likely driven by the 57% PAT growth, strong QoQ rebound, and management raising expectations above prior FY27 guidance.
📈 நீண்ட காலம்Backward integration, Ibuprofen expansion to 9,600 MTPA, and entry into peptides/CDMO platforms via subsidiaries offer sustainable revenue diversification and margin support across FY28.
⚠ அபாய எச்சரிக்கைகள்
Anti-diabetic segment revenue fell 39% YoY in H1FY27
High historical client concentration (top 5 customers account for over 50% of revenue)
👀 கவனிக்க வேண்டியவை
Track the ramp-up of the expanded Ibuprofen capacity (9,600 MTPA) over the next six quarters and pilot scale production at the SMS Peptides subsidiary targeted for Q4FY27.
₹45.63 Cr Tax Demand Vacated as IT Appellate Authority Rules in Favor of SMSPHARMA
SMS Pharmaceuticals has received an appellate order under Section 250 of the Income Tax Act from the Commissioner of Income Tax (Appeals), National Faceless Appeal Centre, allowing the company's appeal. Consequently, an outstanding tax demand of ₹45.63 crore (including interest) for Assessment Year 2023-24 has been vacated. This brings significant relief, as the disputed amount represented approximately 44.7% of the company's TTM PAT of ₹102 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுA tax demand of ₹45.63 crore for AY 2023-24 was struck down after the CIT (Appeals) ruled in favor of SMS Pharmaceuticals.
ஏன் இது முக்கியம்Eliminates a substantial contingent liability that amounted to nearly 45% of annual net profit, removing potential cash outflow pressure.
Vacated Tax Demand: Rs. 45.63 CroresDemand vs TTM PAT: ~44.7%Demand vs Net Worth: ~5.7%Assessment Year: 2023-24Order Date: 30th அக்டோபர், 2026
📅 குறுகிய காலம்Positive sentiment driver as an overhang of potential cash outflow and penalty is removed from the balance sheet.
📈 நீண்ட காலம்Limited operational impact, but strengthens balance sheet clarity by extinguishing a major tax contingency.
⚠ அபாய எச்சரிக்கைகள்
The Income Tax Department could potentially appeal the order before the Income Tax Appellate Tribunal (ITAT).
👀 கவனிக்க வேண்டியவை
Track whether the Income Tax Department files a further appeal before the Income Tax Appellate Tribunal (ITAT) within the statutory limitation period.
CARE Reaffirms SMS Pharma at 'CARE A/A1'; Revises Long-Term Outlook to 'Stable' from 'Positive'
CARE Ratings has reaffirmed SMS Pharmaceuticals' long-term bank facilities rating at 'CARE A' and short-term facilities at 'CARE A1'. The outlook on long-term facilities has been revised from 'Positive' to 'Stable', while the rated long-term amount was enhanced to ₹570.07 crore from ₹350.87 crore. Total bank facilities rated stand at ₹622.90 crore, including ₹349.07 crore in term loans primarily to support capex programs.
உச்சம் நம்பிக்கை
என்ன மாறியதுCARE Ratings reaffirmed ratings but moderated the long-term outlook from 'Positive' to 'Stable' while expanding rated long-term limits by ₹219.20 crore.
ஏன் இது முக்கியம்The revision to a 'Stable' outlook indicates credit metrics are expected to hold steady rather than upgrade near-term, reflecting higher debt utilization for ongoing capex against a current total debt of ₹365 crore.
📅 குறுகிய காலம்Neutral sentiment; credit profile remains investment grade 'A' category with sufficient liquidity headroom across sanctioned limits.
📈 நீண்ட காலம்Reflects execution and funding of capital expansion projects, with stable rating profiles ensuring continuous access to bank financing at standard borrowing costs.
⚠ அபாய எச்சரிக்கைகள்
Increased leverage from debt-funded capex facilities
Outlook moderated from Positive to Stable
👀 கவனிக்க வேண்டியவை
Track the commissioning and cash flow generation from the ₹280 crore backward integration project to see if debt levels normalize and return ratios expand.
SMSPHARMA Q1 Revenue at ₹207 Cr; ₹280 Cr Capex and ₹50 Cr Peptide Infusion Underway
SMS Pharmaceuticals reported a steady Q1FY27 with revenue growing 6% YoY to ₹207 crore and PAT increasing 8% to ₹20 crore. The company is aggressively pursuing a ₹280 crore capex program (representing ~32% of TTM revenue) to be completed by FY27, focusing on capacity expansion and new products. A strategic infusion of ₹50 crore as a loan into SMS Peptides Private Limited highlights a shift toward high-margin R&D. High-value products now contribute 51% of total revenue, helping sustain EBITDA margins at 20%.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized a ₹50 crore funding plan for its peptide subsidiary and reached a milestone where high-value products constitute over half of its revenue mix.
ஏன் இது முக்கியம்The shift toward peptides and high-value APIs, supported by significant capex, is designed to protect margins against generic price erosion and diversify the therapeutic portfolio.
📅 குறுகிய காலம்The stock may see positive sentiment due to stable 20% EBITDA margins and clear visibility on the peptide segment funding.
📈 நீண்ட காலம்Structural growth depends on the successful execution of the ₹280 cr capex and the ability to scale the peptide business to improve return ratios (ROCE currently at 13%).
⚠ அபாய எச்சரிக்கைகள்
High client concentration (Top 5 customers at 56% of FY24 revenue)
Regulatory risk with 88% revenue from regulated markets
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the ₹280 crore capex completion and the commercialization timeline of the peptide R&D facility, which are critical for achieving the 1.75x asset turnover target.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
SMSPHARMA Q1 FY27: 6% Revenue Growth to ₹207 Cr; ₹160 Cr Remaining Capex on Track
SMS Pharmaceuticals reported a steady Q1 FY27 with revenue growing 6% YoY to ₹207.0 Cr and PAT increasing 8% to ₹20.20 Cr. Gross margins expanded by 217 bps to 36% due to backward integration, though EBITDA margins remained flat at 20% due to higher freight and employee costs. The company is progressing on its ₹280 Cr capex plan, with ₹160 Cr (approx. 18% of TTM revenue) remaining to be spent by FY27. Additionally, the board approved a ₹50 Cr loan to its peptide subsidiary to bolster its R&D capabilities.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned into the execution phase of its ₹280 Cr capex while shifting its product mix heavily toward ARV and Anti-migraine APIs to offset a sharp decline in Anti-diabetic revenue.
ஏன் இது முக்கியம்The sustained 20% EBITDA margin despite cost headwinds suggests improved operational resilience from backward integration. The ₹50 Cr loan to the peptide subsidiary indicates a strategic push into high-value, complex therapeutic areas.
📅 குறுகிய காலம்The stock may see neutral to slightly cautious sentiment due to the 13% QoQ revenue decline and the sharp drop in the anti-diabetic segment, despite YoY growth.
📈 நீண்ட காலம்Long-term value depends on the successful commissioning of the remaining ₹160 Cr capex and the ability to scale the peptide R&D facility into a meaningful CDMO contributor by FY27.
⚠ அபாய எச்சரிக்கைகள்
High client concentration (Top 5 customers = 56% of revenue)
Geopolitical risks impacting freight costs
Significant volatility in the Anti-diabetic therapeutic segment
👀 கவனிக்க வேண்டியவை
Investors should monitor the commercialization timeline of the 6-8 niche molecules expected by the end of FY27 and the impact of the ₹50 Cr peptide investment on future CDMO revenue. Watch for margin recovery if geopolitical freight pressures ease as management anticipates.
SMSPHARMA Q1 Profit Up 16% to ₹21.13 Cr; ₹50 Cr Loan to Subsidiary Approved
SMS Pharmaceuticals reported a steady Q1 FY27 with consolidated net profit rising 16% YoY to ₹21.13 Cr. Revenue from operations grew 5.6% YoY to ₹206.96 Cr, though it saw a sequential decline from Q4 FY26. The board approved a significant unsecured loan of up to ₹50 Cr to its 99.99% subsidiary, SMS Peptides, representing approximately 6.2% of the company's net worth. Additionally, the company fixed September 16, 2026, as the record date for the FY26 dividend and re-appointed its CMD for a five-year term.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its Q1 FY27 financial results, established a dividend record date, and committed ₹50 Cr in capital to a subsidiary.
ஏன் இது முக்கியம்The earnings show continued growth in the API business, while the loan to the peptide subsidiary indicates a strategic push into new therapeutic segments.
Q1 Net Profit: ₹21.13 கோடிQ1 வருவாய்: ₹206.96 கோடிLoan to Subsidiary: ₹50 கோடிLoan vs Net Worth: ~6.2%Dividend Record Date: 16-செப்.-2026
📅 குறுகிய காலம்The stock may react positively to the 16% profit growth and the clarity provided on the dividend record date.
📈 நீண்ட காலம்Leadership continuity for five years and expansion into the peptide segment through the subsidiary are structural positives for long-term growth.
⚠ அபாய எச்சரிக்கைகள்
Related-party transaction (₹50 Cr loan to subsidiary)
High client concentration (top 5 customers at 56%)
👀 கவனிக்க வேண்டியவை
Investors should monitor the performance of the new subsidiary, SMS Peptides, and the utilization of the ₹50 Cr loan, alongside the progress of the ongoing ₹280 Cr backward integration project.
SMSPHARMA Q1 PAT Rises 11% YoY to ₹20.2 Cr; Board Approves ₹50 Cr Loan to Subsidiary
SMS Pharmaceuticals reported a consolidated revenue of ₹206.96 Cr for Q1 FY27, reflecting a 5.6% YoY growth but a 13% sequential decline from Q4 FY26. Consolidated Net Profit grew 10.9% YoY to ₹20.20 Cr, driven by improved operational efficiencies despite a rise in employee benefit expenses to ₹23.54 Cr. The board approved a ₹50 Cr unsecured loan to its 99.99% subsidiary, SMS Peptides Private Limited, for business purposes, representing approximately 6.2% of the company's net worth. Additionally, the company confirmed the re-appointment of CMD Ramesh Babu Potluri for a five-year term starting October 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its Q1 FY27 financial results, secured leadership continuity for the next five years, and initiated financial support for its peptide subsidiary.
ஏன் இது முக்கியம்While YoY growth remains positive, the sequential dip in revenue and the ₹50 Cr capital allocation to a subsidiary indicate a transition phase as the company diversifies into new therapeutic areas like peptides.
Consolidated Revenue (Q1 FY27): ₹206.96 கோடிConsolidated PAT (Q1 FY27): ₹20.20 கோடிLoan to Subsidiary: ₹50 கோடிLoan vs Net Worth: ~6.2%YoY Revenue Growth: 5.6%QoQ Revenue Growth: -13.0%
📅 குறுகிய காலம்The stock may see neutral to slightly cautious movement due to the sequential revenue decline, despite the YoY profit growth.
📈 நீண்ட காலம்Long-term prospects depend on the successful ramp-up of the peptide business and the margin benefits from the ongoing backward integration project.
⚠ அபாய எச்சரிக்கைகள்
High client concentration (Top 5 customers = 56% of revenue)
Sequential revenue decline of 13%
Execution risk in the new peptide subsidiary
👀 கவனிக்க வேண்டியவை
Investors should monitor the performance of the new peptide subsidiary and the execution of the ₹280 Cr backward integration project to see if it offsets the 13% sequential revenue decline.
SMS Pharmaceuticals has uncovered a fraudulent scheme involving the illegal claim of 85,000 equity shares by impersonators. The fraud affected 7 original shareholders who held shares in physical form and was discovered during a routine KYC update process. The company has proactively filed a formal complaint with the Economic Offences Wing (EOW), Hyderabad, to protect shareholder interests. While the company is taking legal action, this incident highlights risks associated with physical share certificates.
முக்கிய அம்சங்கள்
Identification of fraudulent claims involving 85,000 equity shares in physical form.A total of 7 original shareholders were targeted using forged and fabricated documents.Company filed a suo motu complaint with the Economic Offences Wing (EOW), Hyderabad, which has registered a case.The fraud involved a common modus operandi with impersonated claimants using identical or nearby addresses.
👀 கவனிக்க வேண்டியவை
Investors still holding physical share certificates should prioritize dematerializing their holdings to prevent impersonation and fraud. Monitor for further updates from the EOW investigation regarding potential systemic lapses or further discoveries.
SMS Pharma FY26 PAT Jumps 47% to ₹102 Cr; Targets 22% EBITDA Margin in FY27
SMS Pharmaceuticals reported a strong FY26 with revenue growing 13% to ₹887 crores and PAT surging 47% to ₹102 crores, aided by a ₹14 crore contribution from associate VKT Pharma. The company successfully expanded its EBITDA margin to 20% through backward integration in key products like Ibuprofen. Management has guided for a 15% revenue growth in FY27 and aims for a record 22% EBITDA margin despite geopolitical logistics challenges. A ₹280 crore brownfield expansion is underway to increase Ibuprofen capacity to 800 MT/month and launch high-margin APIs.
முக்கிய அம்சங்கள்
FY26 PAT increased by 47% YoY to ₹102 crores, while EBITDA grew 23% to ₹171 crores.Ibuprofen capacity is being expanded from 500 MT to 800 MT per month, with completion expected by March 2027.Management targets a historical high EBITDA margin of 22% for FY27, up from 20% in FY26.Filed 12 DMFs/CEPs in FY26 with plans for 10 more in FY27 to diversify the product portfolio.Invested ₹130 crores out of a planned ₹280 crores capex for brownfield expansion and backward integration.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the Ibuprofen capacity expansion and the stabilization of solvent costs, which impacted Q4 margins. The stock remains attractive due to strong backward integration and a clear roadmap for high-margin API launches in FY28.
SMSPHARMA FY26 PAT Surges 47% to ₹102 Cr; EBITDA Margins Expand to 19%
SMS Pharmaceuticals reported a strong performance for FY26, with consolidated PAT growing 47% YoY to ₹102 crore, significantly aided by the share of profit from its associate, VKT Pharma. Annual revenue increased by 13% to ₹887 crore, while EBITDA margins expanded by 155 bps to 19% due to strategic backward integration and an improved product mix. The company is currently executing a ₹280 crore Capex plan scheduled for completion by FY27 to drive future capacity. Additionally, the Board has recommended a final dividend of ₹0.40 per share.
முக்கிய அம்சங்கள்
FY26 PAT increased by 47% YoY to ₹102 crore, with EPS rising 37% to ₹11.15.EBITDA margins improved to 19% in FY26, driven by backward integration and a 47% share of high-value products.Revenue from operations grew 13% YoY to ₹887 crore, despite a slight 4% YoY dip in Q4 revenue to ₹238 crore.A ₹280 crore Capex program is on track for completion by FY27, focusing on brownfield and greenfield expansions.The Board recommended a final dividend of ₹0.40 (40%) per equity share for the fiscal year.
👀 கவனிக்க வேண்டியவை
Investors should view the strong margin expansion and the successful contribution from VKT Pharma as positive indicators of operational efficiency. The ongoing Capex and target to double R&D investment suggest a robust growth pipeline, making it a stock to hold for long-term value.
SMSPHARMA FY26 PAT Jumps 48% to ₹102 Cr; Recommends ₹0.40 Dividend
SMS Pharmaceuticals reported a strong FY26 performance with PAT growing 48% YoY to ₹101.98 crore, bolstered by a ₹14 crore contribution from its associate, VKT Pharma. Annual revenue increased by 13% to ₹886.87 crore, driven by significant growth in Anti-Retro Viral (55%) and Anti-epileptic (85%) segments. EBITDA margins expanded by 155 basis points to 19% for the full year, attributed to successful backward integration and a strategic shift in product mix. The company provided optimistic guidance for FY27, targeting over 15% revenue growth and 20% EBITDA margins.
முக்கிய அம்சங்கள்
Full-year PAT increased 48% YoY to ₹102 crore, with FY26 EBITDA margins rising 155 bps to 19%.Revenue from Anti-Retro Viral (ARV) APIs surged 55% YoY to ₹251.80 crore, now representing 28% of total revenue.The Board recommended a final dividend of ₹0.40 per share (40% of face value).A ₹280 crore Capex program is on track for FY27 completion to enhance R&D and manufacturing capacity.Management guidance for FY27 includes >15% revenue growth and EBITDA margins around 20%.
👀 கவனிக்க வேண்டியவை
Investors should focus on the successful margin expansion through backward integration and the strong FY27 guidance. The stock remains attractive for long-term investors given the ongoing ₹280 crore capacity expansion and diversifying product portfolio.
SMS Pharma FY26 Net Profit Rises 28% to ₹87.6 Cr; Recommends ₹0.40 Dividend
SMS Pharmaceuticals reported a strong full-year performance for FY26, with net profit growing 28.1% YoY to ₹87.61 crore. Annual revenue from operations increased by 13.3% to ₹886.87 crore, although Q4 revenue saw a slight year-on-year dip. The board has recommended a final dividend of ₹0.40 per share. Additionally, the company strengthened its capital base by converting 50 lakh warrants into equity shares, raising approximately ₹47.6 crore.
முக்கிய அம்சங்கள்
Full-year FY26 Net Profit grew 28.1% to ₹8,760.93 lakhs compared to ₹6,838.12 lakhs in FY25.Annual Revenue from Operations increased 13.3% to ₹88,687.10 lakhs from ₹78,274.81 lakhs.Recommended a final dividend of ₹0.40 per equity share (40% of face value) for FY26.Converted 50,00,000 warrants into equity shares, increasing paid-up capital to ₹936.52 lakhs.Approved shifting the registered office to Kondapur, Hyderabad, effective May 25, 2026.
👀 கவனிக்க வேண்டியவை
Investors should view the robust annual profit growth and dividend declaration as positive signs of operational efficiency. Monitor the impact of the equity dilution from warrant conversion on future EPS.
SMS Pharma Tax Demand Slashed to ₹40.28 Lakhs from ₹7.19 Crores
SMS Pharmaceuticals Limited has received a rectification order from the Income Tax Department regarding the Assessment Year 2018-19. The order has significantly reduced the previous tax demand from ₹7.19 crores to just ₹40.28 lakhs following a rectification application filed by the company. While an appeal is still pending before the Commissioner of Income Tax (Appeals), this reduction mitigates a significant potential financial liability. Management believes there will be no material impact on the company's financial or operational activities at this stage.
முக்கிய அம்சங்கள்
Tax demand for AY 2018-19 reduced by over 94% from ₹7.19 crores to ₹40.28 lakhsRectification order received under Section 154 of the Income-tax Act, 1961Company has filed an appeal before the Commissioner of Income Tax (Appeals) regarding the remaining demandApplication filed to keep penalty proceedings under Section 270A in abeyance until appeal disposal
👀 கவனிக்க வேண்டியவை
The substantial reduction in tax liability is a positive development for the company's cash flow outlook. Investors should maintain their current positions as the remaining demand is not financially material to the company's overall operations.
SMS Pharma Receives ₹7.19 Crore Income Tax Demand for AY 2018-19
SMS Pharmaceuticals Limited has received a demand notice of ₹7.19 crores from the Income Tax Department for the Assessment Year 2018-19. The demand arises from the disallowance of deductions under Section 35 of the Income Tax Act and the addition of certain income. Additionally, the department has initiated penalty proceedings for the alleged under-reporting of income. The company is currently evaluating the order and intends to seek legal remedies through the appropriate appellate forums.
முக்கிய அம்சங்கள்
Income tax demand of ₹7.19 crores raised for the Assessment Year 2018-19.Order involves disallowance of deductions under Section 35 related to scientific research expenditure.Penalty proceedings under Section 270A initiated for alleged under-reporting of income.Company is reviewing the order and plans to contest it before the appropriate forum.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the company's appeal against this demand and check for any related financial provisions in upcoming quarterly results. While the demand is a potential liability, the company's intent to contest it may delay any immediate cash outflow.
SMS Pharma Q3FY26 PAT Grows 29% YoY to ₹23.5 Cr; EBITDA Margins Cross 20%
SMS Pharmaceuticals reported a strong Q3FY26 with revenue growing 21% YoY to ₹210.45 crore, driven by volume growth in key APIs. Net profit (PAT) increased by 29% YoY to ₹23.47 crore, while EBITDA margins improved to 20.74% due to backward integration benefits. The company achieved its annual target of 10 filings ahead of schedule and is on track with its ₹280 crore capex plan. Management maintained a positive outlook for FY26, targeting 20% revenue growth and sustained margins.
முக்கிய அம்சங்கள்
Revenue from operations grew 21% YoY to ₹210.45 crore in Q3FY26.PAT for 9MFY26 surged 42% YoY to ₹69.27 crore, reflecting strong operational leverage.EBITDA margins expanded by 158 bps YoY to 20.74%, supported by backward integration.Significant 9MFY26 growth of 85% each in ARV, Anti-epileptic, and Anti-anginal therapeutic segments.₹280 crore capacity expansion programme is on track for completion by FY27.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's progress on its ₹280 crore capex plan and its ability to maintain the 20% EBITDA margin guidance. The strong growth in niche therapeutic areas and early R&D filings suggest a robust future pipeline.
SMS Pharma Reports Zero Deviation in Utilization of Rs 114.30 Cr Raised via Warrants
SMS Pharmaceuticals has confirmed no deviation in the utilization of Rs 114.30 crores raised through a preferential issue of 90 lakh warrants. As of December 31, 2025, the company has utilized Rs 80.93 crores, primarily focusing on capital expenditure for production expansion and backward integration. A sum of Rs 33.35 crores has been temporarily deployed toward working capital to reduce finance costs, which the Audit Committee has advised be re-transferred for project execution as needed. The company is progressing with its plan to set up new production blocks for Key Starting Materials (KSM).
முக்கிய அம்சங்கள்
Total issue size of Rs 114.30 crores fully raised following conversion of 90,00,000 warrants.Cumulative utilization of funds stands at Rs 80.93 crores as of December 31, 2025.Rs 48.05 crores utilized for CapEx and expansion of production capacities against an allocation of Rs 62.87 crores.Temporary deployment of Rs 33.35 crores in working capital to optimize finance costs pending project execution.Funds are being directed toward backward integration of Key Starting Materials (KSM) for existing and pipeline products.
👀 கவனிக்க வேண்டியவை
Investors should track the completion of the production capacity expansion and KSM backward integration, as these are key to long-term margin improvement. The temporary use of funds for working capital is a standard treasury management practice and does not indicate a change in the company's strategic objectives.
SMSPHARMA Q3 Net Profit Rises 29% YoY to ₹23.47 Cr; Board OKs ₹7 Cr Subsidiary Investment
SMS Pharmaceuticals reported a strong year-on-year performance for Q3 FY26, with consolidated revenue growing 21.4% to ₹210.45 crore compared to ₹173.35 crore in the same quarter last year. Net profit for the quarter stood at ₹23.47 crore, a significant 28.7% increase from ₹18.24 crore YoY, although it saw a slight sequential dip from ₹25.31 crore in Q2. For the nine-month period, the company demonstrated robust growth with profits surging 42% to ₹69.28 crore. Additionally, the board approved a strategic investment of up to ₹7 crore in its subsidiary, SMS Peptides Private Limited, to strengthen its presence in the peptide segment.
முக்கிய அம்சங்கள்
Consolidated Revenue from Operations grew 21.4% YoY to ₹210.45 crore in Q3 FY26.Net Profit after tax increased by 28.7% YoY to ₹23.47 crore.Nine-month (9M FY26) Net Profit reached ₹69.28 crore, a 41.9% increase over 9M FY25.Board approved a further investment of up to ₹7 crore in subsidiary SMS Peptides Private Limited.Basic EPS for the quarter improved to ₹2.59 from ₹2.15 in the previous year's corresponding quarter.
👀 கவனிக்க வேண்டியவை
Investors should take note of the strong year-on-year growth and the strategic focus on the peptide segment. While there was a minor sequential decline, the overall nine-month trajectory remains robust, suggesting healthy operational momentum.
SMS Pharmaceuticals has successfully incorporated a new wholly owned subsidiary, SMS coLab Private Limited, as of December 23, 2025. This new entity is established as a greenfield project to focus on the research, development, and manufacturing of pharmaceutical products in new therapeutic categories. The company invested an initial cash consideration of Rs. 1,00,000 for a 100% equity stake, with an authorized capital of Rs. 15,00,000. This strategic move aims to expand the company's footprint in the formulations sector and enhance its global market reach.
முக்கிய அம்சங்கள்
Incorporation of 'SMS coLab Private Limited' as a 100% subsidiary on December 23, 2025.Initial paid-up capital of Rs. 1,00,000 with an authorized capital of Rs. 15,00,000.Subsidiary to focus on greenfield projects in new therapeutic categories and R&D.Business scope includes manufacturing, marketing, and global distribution of APIs and formulations.The move is intended to establish strategic partnerships and joint ventures globally.
👀 கவனிக்க வேண்டியவை
Investors should view this as a long-term growth signal and monitor future CAPEX announcements related to this greenfield project. No immediate impact on earnings is expected as the subsidiary is yet to commence operations.
SMS Pharma: USFDA inspects Vizag facility, issues one minor observation
SMS Pharmaceuticals Limited announced the successful completion of a USFDA inspection at its API manufacturing facility in Visakhapatnam from December 8 to December 12, 2025. The inspection concluded with one minor procedural observation in Form 483, which does not relate to data integrity. The Vizag facility is a 3,000 KL flagship API manufacturing facility with multiple global regulatory approvals. This marks the 4th inspection for this facility and the 12th across SMS Pharma's manufacturing sites.
முக்கிய அம்சங்கள்
USFDA inspection completed at Vizag facility from December 8 to December 12, 2025One minor observation in Form 483 issued by USFDAVizag facility is a 3,000 KL API manufacturing facilityFacility has 12 regulatory approvals including USFDA, WHO-GMP and EU-GMPThis is the 4th USFDA inspection for the Vizag facility
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's response to the USFDA observation and any subsequent updates. The successful inspection supports continued API supply to international markets.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
